Kmt2a cooperates with menin to suppress tumorigenesis in mouse pancreatic islets

Wenchu Lin1,2, Joshua M Francis2,3, Hong Li1

  • 1a High Magnetic Field Laboratory, Chinese Academy of Sciences , Hefei , Anhui , P.R. China.

Cancer Biology & Therapy
|November 2, 2016
PubMed

Insights

Inactivating Kmt2a in Men1-deficient mice accelerated pancreatic neuroendocrine tumor (PanNET) development and increased cell proliferation. This new Kmt2a/Men1 double knockout mouse model aids in studying advanced PanNETs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Pancreatic neuroendocrine tumors (PanNETs) incidence is rising, necessitating deeper molecular pathology understanding.
  • Current therapeutic options for PanNETs are limited, highlighting the need for advanced preclinical models.
  • The Men1 knockout mouse model mimics early PanNET development, serving as a basis for improved models.

Purpose of the Study:

  • To investigate the role of KMT2A in PanNET development in conjunction with MEN1.
  • To develop and characterize a novel mouse model for studying advanced PanNETs.

Main Methods:

  • Generation of a Kmt2a/Men1 double knockout mouse model.
  • Analysis of tumor development, cell proliferation, and lifespan in the mouse model.
  • Investigating the interaction between Menin and KMT2A/KMT2B histone methyltransferases.

Main Results:

  • Inactivation of Kmt2a in Men1-deficient mice accelerated pancreatic islet tumorigenesis.
  • Tumor-bearing mice exhibited shortened average lifespans.
  • Increased cell proliferation was observed in double knockout mouse pancreatic islet tumors.

Conclusions:

  • The Kmt2a/Men1 double knockout mouse is a valuable model for studying advanced PanNETs.
  • This model facilitates preclinical testing and research into PanNET molecular pathology.
  • Understanding the interplay between KMT2A and MEN1 is crucial for PanNET research.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K